lopinavir/ritonavir / Generic mfg. - LARVOL DELTA

Navigating Therapeutic Frontiers: A Meta-review and Meta-analysis of COVID-19 Treatment Options. (PubMed, J Res Pharm Pract) - "285 reviews with 152 meta-analyses were included, The analysis of systematic reviews contents indicated that most reviewed drugs were as follows: chroquine/hydroxychloroquine (n = 48), tocilizumab (n = 39), remdesivir (n = 25), corticosteroids (n = 25), JAK inhibitors (n = 12), colchicine (n = 11), ivermectin (n = 8), anakinra (n = 7), favipravir (n = 7), lopinavir/ritonavir (n = 6), ACEI/ARB (n = 6), azithromycin (n = 4), sofosbuvir (n = 4), and Vitamin D (n = 4)...lower requirement for mechanical ventilation and intensive care unit admission and a shorter hospital length of stay was observed with the tocilizumab, JAKIs, anakinra, corticosteroids and sofosbuvir Only one third of the included reviews had 70% quality based on the AMSTAR scale assessment. The results of this study have the potential to be a useful tool for the translation of health evidence and for designing the decision support systems for evidence synthesis."

Journal • Retrospective data • Review • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Longitudinal Clinical and Molecular Characterization of a Single Pediatric Case of Vertically Acquired HIV-1 Subtype C with Baseline Resistance to Protease Inhibitors. (PubMed, Microorganisms) - "Stanford HIVdb predicted high-level resistance to lopinavir/ritonavir, atazanavir/ritonavir, lamivudine, and emtricitabine; low-level resistance to darunavir/ritonavir and abacavir; and preserved susceptibility to tenofovir, zidovudine, and the evaluated NNRTIs...Following treatment optimization with an integrase inhibitor-based regimen and subsequent transition to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), HIV-1 RNA became Target Not Detected (TND) from November 2024 onward. At the latest follow-up, the CD4 count was 877 cells/µL, the CD8 count was 722 cells/µL, and the CD4:CD8 ratio had improved to 1.21, indicating substantial immune recovery. This single-patient case highlights the clinical value of baseline genotypic resistance testing and individualized, genotype-guided antiretroviral therapy in achieving durable virological suppression in pediatric HIV."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics • CD4 • CD8

POPS or POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (clinicaltrials.gov) - P=N/A | N=5000 | Recruiting | Sponsor: Duke University | Trial completion date: Jul 2027 ➔ Dec 2026 | Trial primary completion date: Mar 2027 ➔ Nov 2026

Trial completion date • Trial primary completion date • ADHD (Impulsive Aggression) • Asthma • Attention Deficit Hyperactivity Disorder • Bronchopulmonary Dysplasia • Cardiovascular • CNS Disorders • Dermatology • Developmental Disorders • Endocrine Disorders • Genetic Disorders • Gynecology • Heart Failure • Hematological Disorders • Hemophilia • Hypertension • Immunology • Infectious Disease • Insomnia • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Pain • Pneumonia • Psychiatry • Pulmonary Arterial Hypertension • Pulmonary Disease • Rare Diseases • Renal Disease • Respiratory Diseases • Sleep Disorder

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov) - P=N/A | N=205 | Terminated | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Completed ➔ Terminated; The study was closed to accrual early based on Study Monitoring Committee review indicating that the study objectives had either been achieved or could not be met within a reasonable timeframe for the then-open arms.

Trial termination • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) (clinicaltrials.gov) - P2 | N=118 | Recruiting | Sponsor: Dar Bioscience, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Human Papillomavirus Infection • Infectious Disease • Oncology

Association between initial antiretroviral therapy regimens and virological outcomes in HIV-infected individuals in Taizhou, Zhejiang Province, 2006-2025 (PubMed, Zhonghua Liu Xing Bing Xue Za Zhi) - "Apart from the two nucleotide reverse transcriptase inhibitors backbone drugs, the proportions of selecting efavirenz (EFV), nevirapine (NVP), lopinavir/ritonavir (LPV/r), dolutegravir (DTG), and other drugs as the third drug were 80.22% (2 976/3 710), 15.12% (561/3 710), 1.32% (49/3 710), 1.08% (40/3 710), and 2.26% (84/3 710) respectively-205 individuals (5.53%) with virological failure. After adjusting for the educational level of the study subjects, initial CD4+T lymphocyte counts, initial viral load, time interval from diagnosis to ART initiation, and the year of ART initiation, the risk of virological failure in the NVP group was 4.93 times that of the [integrase inhibitors/protease inhibitors(INSTI/PI)] group (95%CI: 1.73-14.05), and 2.72 times that of the EFV group (95%CI: 1.92-3.85). Among HIV-infected individuals in Taizhou who received NVP-based initial ART regimens between 2006 and 2025, the risk of virological failure was higher than among those who..."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Tolerability of lopinavir/ritonavir versus dolutegravir in ART regimens. (PubMed, AIDS) - No abstract available

Journal

National cross-sectional survey on acquired HIV drug resistance in Haiti in 2023: warnings resistance to dolutegravir (AIDS 2026) - "3.77% of HIVs were resistant to dolutegravir and bictegravir, 4.4% to cabotegravir, 4.72% to raltegravir, and 5.03% to elvitegravir. Additionally, 15.19% of the viral strains were resistant to abacavir, 13.92% to lamivudine and emtricitabine, 6.65% to zidovudine, 8.23% to stavudine and didanosine, and 4.13% to tenofovir...Furthermore, some HIVs strains developed resistance against efavirenz (49.37%), nevirapine (50%), Rilpivirine (20.25%), Etravirine (12.66%), and doravirine (3.61%). Finally, HIV genome resistance was 0.63% against atazanavir/ritonavir and indinavir/ritonavir, 0.95% against lopinavir/ritonavir and 0.32% against darunavir/ritonavir. HIV acquired pharmacoresistance is moderate in Haiti and requires innovating adapted strategy for preventing its development, its transmission, and for protecting PLHIV health, while emphasizing on children and male individuals."

Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (clinicaltrialsregister.eu) - P4 | N=290 | Sponsor: Gilead Sciences, Inc.

New P4 trial • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Community-led patent opposition case-study for HIV treatment access in Georgia (AIDS 2026) - " TBpeople Georgia submitted patent opposition filings against key antiretroviral drug patents (e.g., lopinavir/ritonavir, Islatravir and Doravirine), prepared proposal on legislative amendments on restricting of subject matter of protection of utility model patents that could limit competition and inflate treatment costs. The Georgian experience demonstrates that practice of a request to re-examine the Georgian ever greening patent for lopinavir/ritonavir opens a door for future similar actions on medicine access and affordability, initiated by community based organizations."

Case study • Clinical • Human Immunodeficiency Virus • Infectious Disease

Dolutegravir markedly improves 6- and 12-month viral suppression in children ≤5 Years, South Africa (AIDS 2026) - " Among children born mid-2018 to mid-2024, we identified those aged =5 years who started ART on DBR or lopinavir-ritonavir (LPV/r)-based regimens, or switched to DBR. A markedly higher proportion of young children initiating DBR (vs LPV/r) achieved VS. Among children who switched to DBR, VS was notably lower when VL at switch was =1000, emphasizing the need for close monitoring in this group. This is the largest programme-based cohort of children aged =5 years receiving DBR described to date, supporting DBR as an effective first-line in routine paediatric HIV care."

Clinical • Human Immunodeficiency Virus • Infectious Disease

Dolutegravir coverage and viral suppression among adolescents and young adults living with HIV in Africa: findings from nine nationally-representative surveys, 2019-2023 (AIDS 2026) - "ALWH aged 15-24 years (sample n = 1827) were categorized into one of three mutually exclusive treatment groups: DTG-based regimen, non-DTG-based regimens (Efavirenz, Atazanavir/ritonavir, Nevirapine, Lopinavir/ritonavir); and not currently on any treatment. DTG-based regimen is superior to other ART options in achieving viral load suppression in adolescents. To reach global targets, programs should continue prioritizing DTG-based ART while intensifying efforts to initiate treatment for all individuals currently not on ART. Additionally, population-based viral suppression for ALWH on DTG remains lower than observed in clinical trials."

Clinical • Human Immunodeficiency Virus • Infectious Disease

Effect of transitioning to dolutegravir versus remaining on lopinavir/ritonavir on virologic outcomes among children and adolescents with HIV in South Africa: a target trial emulation (AIDS 2026) - "Our findings from this first large-scale, causal analysis of the impact of transitioning from lopinavir/ritonavir to dolutegravir support WHO guidelines recommending dolutegravir-based ART for CALWH already virally suppressed on lopinavir/ritonavir-based regimens."

Clinical • Human Immunodeficiency Virus • Infectious Disease

Sustained undetectable intact reservoir in early treated infants in Africa (AIDS 2026) - "Lopinavir and ritonavir (LPV/r) levels were measured concomitantly with reservoir and VL. Early-treated infants, particularly with protective HLA can achieve durable undetectable intact proviral DNA, suggesting extremely small or absent intact reservoir. Those infants are strong candidates for ATI studies. Additionally, undetectable total HIV-DNA by ddPCR reliably identified infants with absent or minimal intact provirus by IPDA, supporting ddPCR as an effective initial screening tool for cure-related studies."

Human Immunodeficiency Virus • Infectious Disease • CD4

Multivariate control charts based on Mahalanobis distance for bivariate quality monitoring in petrochemical and pharmaceutical analyses. (PubMed, Anal Bioanal Chem) - "One ritonavir-lopinavir dataset provided an illustrative action-level exceedance, suggesting how a covariance-adjusted statistic may flag localized joint deviations; however, this single event should not be interpreted as definitive validation of fault-detection capability. A permutation-based resampling strategy was used to examine the variability of control thresholds and signal probabilities across alternative historical-monitoring partitions. Overall, the results support the feasibility, interpretability, and reproducibility of the proposed bivariate workflow as a complementary tool for routine analytical monitoring, while indicating that more rigorous validation with independent datasets containing known deviations is required before broader claims regarding fault-detection performance can be made."

Journal

Impact of Dolutegravir-, Lopinavir/Ritonavir-, and Efavirenz-Based Antiretrovirals on Piperaquine Pharmacokinetics in Ugandan Children Living with HIV. (PubMed, Clin Pharmacol Ther) - "Efavirenz and lopinavir/ritonavir have opposing effects on piperaquine exposure in children living with HIV, which may impact efficacy and toxicity, respectively, although co-administration in this study did not yield concerning safety findings. Dolutegravir reduced only terminal concentrations significantly, which may shorten the duration of post-treatment chemoprophylaxis."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Malaria

Major protease inhibitor drug resistance mutations among patients with virological failure on second-line antiretroviral therapy in Zimbabwe: a retrospective cross-sectional study. (PubMed, Virol J) - "Major PI DRMs and multiclass HIVDR were common among PLWH with VF on PI-based second-line ART. Routine VL monitoring and early resistance testing are needed to detect and guide second-line ART failure in Zimbabwe."

Journal • Observational data • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Mapping the intellectual landscape of malaria drug repurposing: a systematic analysis of the 51 most cited studies. (PubMed, Malar J) - "The convergence of computational power and biological insight has generated a rich pipeline of repurposable candidates. A quantitative analysis revealed molecular docking as the most frequent (31.4% of studies) and successful strategy, though in vivo preclinical evaluation yielded the highest validation score. Future success hinges on rigorous experimental validation, lead optimization, and advancing the most promising agents into clinical trials to address the urgent need for novel antimalarial therapies."

Journal • Review • Infectious Disease • Malaria • Oncology

Delayed Onset of Diabetic Ketoacidosis After Bictegravir Antiretroviral Therapy With Complete Resolution Upon Discontinuation (ENDO 2026) - "Clinical Case: A 59-year-old female with virally suppressed HIV on lopinavir/ritonavir and tenofovir disoproxil fumarate/lamivudine was transitioned to bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC) in June 2024 to simplify her ART regimen...Following BIC/TAF/FTC discontinuation and transition to a protease inhibitor-based ART regimen with darunavir/cobicistat/TAF/FTC, glycemia rapidly normalized (A1c 6.4%, random BG 101 mg/dL, estimated A1c by CGM 5.7%, time-in-range 100%) over approximately 7 weeks, allowing discontinuation of all antidiabetic medications... Compared to previous reports of BIC-induced hyperglycemia, this case is notable for its delayed onset, suggesting a broader timeline of risk. Consistent with prior reports, improvement in glycemia was observed following discontinuation of BIC. This case highlights the importance of ongoing metabolic monitoring with BIC-based ART, even beyond the early treatment period and suggests consideration of..."

First-in-human • Late-breaking abstract • Diabetes • Dyslipidemia • Human Immunodeficiency Virus • Immunology • Infectious Disease • Metabolic Disorders

Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT). (PubMed, BMJ Open) - "Subcutaneous schwannomas of the skin (CS) are common in the NF2 population.This trial involves the repurposing of medications already licensed for HIV-ritonavir and lopinavir (Kaletra and Norvir)-that have been shown to reduce tumour growth by reducing cell proliferation in human schwannoma and meningioma tumour cell cultures...Following analysis of trial data, the trial results will be written up for publication in a peer-reviewed scientific journal and will be disseminated at conferences. ISRCTN10422213."

Journal • Brain Cancer • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Meningioma • Neurofibromatosis • Oncology • Rare Diseases • Solid Tumor • NF2

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. (PubMed, Front Pharmacol) - "The model was calibrated using 175-300 mg/m2 monotherapy data and was validated across a 33-750 mg/m2 dose range, including drug-drug interactions with ketoconazole, sorafenib, and lopinavir/ritonavir. The mechanistically informed and validated whole-body PBPK model reliably describes dose-dependent irinotecan and SN-38 pharmacokinetics and UGT1A1/CYP3A-mediated drug-drug interactions. This framework provides a clinically relevant tool for enzyme-mediated DDI risk assessment and for exploratory simulation of dose-exposure relationships under standard irinotecan regimens."

Journal • CYP3A4 • UGT1A1 • UGT1A9

Prescription of colchicine and NSAIDs for acute gout flares in severe chronic kidney disease and colchicine in major drug–drug interactions: evidence from an electronic health-record based gout register (EULAR 2026) - "Strong inhibitors included atazanavir, clarithromycin, cobicistat, darunavir, fluconazole, ketoconazole, lopinavir, ritonavir, nirmatrelvir–ritonavir, voriconazole, and ciclosporin. Moderate to weak inhibitors included erythromycin, verapamil, amiodarone, diltiazem, and dronedarone...Conclusions Colchicine was frequently prescribed for acute gout flares in patients with severe chronic kidney disease despite society guideline recommendations, although co-prescription with strong CYP3A4 or P-glycoprotein inhibitors was uncommon. These findings suggest partial adherence to recommendations and warrant further evaluation of colchicine safety in patients with severe chronic kidney disease."

Chronic Kidney Disease • Gout • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatology • CYP3A4

A Phase 2a Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV). (clinicaltrials.gov) - P2 | N=118 | Not yet recruiting | Sponsor: Daré Bioscience, Inc.

New P2 trial • Human Papillomavirus Infection • Infectious Disease • Oncology

Pharmacogenomics of current antiretroviral drugs. (PubMed, Pharmacogenomics) - "We searched Pharmacogenomics Knowledgebase (PharmGKB®) for abacavir, tenofovir disoproxil fumarate, tenofovir alafenamide, lamivudine, emtricitabine, dolutegravir, elvitegravir, raltegravir, bictegravir, cabotegravir, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir, lenacapavir, rilpivirine and doravirine. Actionable pharmacogenetic associations with antiretroviral drugs remain limited to abacavir. Future research should prioritize replicating pharmacogenetic associations across diverse populations and establishing clinical relevance."

Biomarker • Journal • Review • Human Immunodeficiency Virus • Infectious Disease • HLA-B • UGT1A1

Vertical Transmission of Toxoplasma gondii during Late Gestation: Efficacy of Spiramycin-Nanoparticles and Aluvia (lopinavir/ritonavir) in Offspring of Infected Mice. (PubMed, Microb Pathog) - "In conclusion, spiramycin-loaded CNPs and Aluvia showed promising results, particularly in significantly reducing parasite burden in the offspring's brain, indicating their potential ability to cross the placenta and the fetal blood brain-barrier (BBB). These findings provide useful data on the transmission of Toxoplasma to offspring organs and highlight the promise of spiramycin nanoparticle formulation and Aluvia in improving therapeutic outcomes for congenital toxoplasmosis and minimizing the severity of fetal infection."

Journal • Preclinical • Infectious Disease